News coverage about MannKind Corporation (NASDAQ:MNKD) has trended somewhat positive on Sunday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MannKind Corporation earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.3703363683079 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- MNKD Aug 2017 1.500 call (finance.yahoo.com)
- Share Performance in View for MannKind Corporation (NASDAQ:MNKD) - Jonesboro Recorder (jonesbororecorder.com)
- Investor’s Alert: Mannkind Corporation (MNKD) - Post Registrar (postregistrar.com)
- MannKind Corporation to Hold 2017 Second Quarter Financial Results Conference Call on August 7, 2017 - GlobeNewswire (press release) (globenewswire.com)
- MannKind: Assessing The Insurance Landscape For Afrezza - Seeking Alpha (seekingalpha.com)
Several analysts have recently weighed in on the company. ValuEngine cut MannKind Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Piper Jaffray Companies set a $1.00 price target on MannKind Corporation and gave the stock a “sell” rating in a report on Thursday, May 11th. J P Morgan Chase & Co reaffirmed a “sell” rating on shares of MannKind Corporation in a research note on Thursday, May 11th. Finally, S&P Equity Research cut their price objective on MannKind Corporation from $1.04 to $0.83 in a research note on Monday, May 8th.
MannKind Corporation (NASDAQ MNKD) traded up 3.13% during trading on Friday, hitting $1.32. The company had a trading volume of 1,127,724 shares. The company’s 50 day moving average price is $1.38 and its 200-day moving average price is $1.20. The stock has a market capitalization of $133.33 million, a price-to-earnings ratio of 0.89 and a beta of 3.33. MannKind Corporation has a 1-year low of $0.67 and a 1-year high of $5.10.
MannKind Corporation (NASDAQ:MNKD) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.08. The business had revenue of $3 million during the quarter, compared to the consensus estimate of $3.50 million. The firm’s revenue for the quarter was up 2900.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.06) EPS. On average, analysts expect that MannKind Corporation will post ($0.96) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://stocknewstimes.com/2017/07/30/mannkind-corporation-nasdaqmnkd-getting-somewhat-favorable-news-coverage-study-shows-updated.html.
MannKind Corporation Company Profile
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
